Medipal
Medipal is a South Korea-based healthcare AI company offering AfterDoc, a SaaS patient management platform, and Medipal AI, a multi-agent AI platform that automates patient communication and hospital workflows for 500+ Korean hospitals and clinics.
- Company typePrivate
- Founded2020
- HeadquartersMapo, South Korea
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Medipal does
Medipal is a South Korea-based healthcare AI company founded in 2019–2020, headquartered in Seoul, that operates AfterDoc, a subscription SaaS platform for hospitals and clinics to manage re-examination scheduling and post-treatment patient communication. The company has expanded its offering into Medipal AI, a hospital-specialized AI agent platform that automates patient inquiries across phone, KakaoTalk, Naver Talk Talk, Instagram, and international channels (LINE, WhatsApp, WeChat), and collaborates with medical staff to optimize in-hospital workflows. The AI agents are trained on hospital-specific data and evolve through reinforcement learning from medical-staff interactions, drawing on a proprietary base of more than 20 million patient session data points accumulated since June 2020 across 500+ facilities and 1.5 million patients.
Underlying technology combines domain-specialized AI agents with multi-channel messaging integrations and structured patient-data processing. A one-click activation model bundles the agent suite into a single platform, and the system supports hospital-specific configuration of AI operating scope and learning environment. Medipal offers no disclosed APIs or SDKs; the platform is accessed via web (afterdoc.ai) and delivered through direct enterprise sales.
The business model is B2B SaaS sold on a subscription basis to healthcare institutions, with quote-based enterprise pricing (Contact Sales motion). Customers include general hospitals (e.g., Yangji Hospital, Incheon Sejong Hospital, Park Jin-young Hospital) and aesthetic/cosmetic clinics (e.g., AB Plastic Surgery, Dr. Evers, B&B Light). The company is venture-backed, with approximately 7 billion KRW (~$5M) raised across seed (2020), pre-Series A (2022), and Series A (2023) rounds from investors including KT Investment, Insight Equity Partners, Base Investment, Digital Healthcare Partners, and Sopoong Ventures. Leadership consists of founder-CEO Kang Jong-il.
Medipal firmographics
Firmographics- Name
- Medipal
- Legal name
- (주)메디팔
- Website
- https://medipal.co.kr
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Medipal is a South Korea-based healthcare AI company offering AfterDoc, a SaaS patient management platform, and Medipal AI, a multi-agent AI platform that automates patient communication and hospital workflows for 500+ Korean hospitals and clinics.
- Ownership category
- akta.pro rank
Medipal industry classification
Industry- Product category
- Healthcare Workflow Automation Software
- NAICS
- Computer Systems Design and Related Services (54151)
- SIC
- Services-Health Services (8000), Services-Prepackaged Software (7372)
- akta.pro primary industry
- Adherence, Reminders & Engagement Automation (Medication/Follow-up) (HLACAEAJ)
- akta.pro secondary industry
- Virtual Nursing, Telemonitoring & Command Center Platforms (HLACAFAH)
Keywords
Where Medipal is headquartered
LocationHeadquarters
- HQ city
- Mapo
- HQ country
- South Korea
- HQ region
- Asia
Offices1 record
Markets served
Medipal business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations
Revenue model
- SaaS Subscription for Healthcare Institutions: AfterDoc is a subscription-based SaaS platform for hospitals and clinics providing patient management, re-examination management, and post-treatment management solutions. The platform is sold as a subscription to healthcare institutions.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Medipal product offering
Product offeringCore offering
Medipal sells the Medipal AI platform and AfterDoc, a subscription SaaS solution that deploys domain-specialized AI agents in hospitals and clinics to automate patient inquiries (across KakaoTalk, Naver Talk Talk, LINE, WhatsApp, WeChat, Instagram, and phone), re-examination scheduling, post-treatment management, and broader in-hospital workflow optimization. The platform is sold on a recurring subscription basis to healthcare institutions in South Korea, with hospital-specific AI training and one-click agent activation.
Product overview
Medipal operates a dual-product portfolio consisting of Medipal AI (a comprehensive AI agent platform) and AfterDoc (the foundational patient management SaaS). Medipal AI is the primary platform offering multiple specialized AI agents that collaborate with medical staff across all hospital workflows, integrating patient communications and AI operations into a unified workspace. AfterDoc serves as the core patient management module focused on aftercare, re-examination, and post-treatment management. Both products are designed to work together, with AfterDoc providing the patient management foundation that Medipal AI extends with advanced AI agent capabilities for comprehensive hospital automation.
Differentiator
Problem solved
Functional benefit
Brands
- AfterDoc: Aftercare SaaS platform for hospitals and clinics that provides AI-powered patient management, re-examination management, and post-treatment management solutions. The platform includes AI agents for patient communication, inquiry handling, and hospital workflow optimization.
Products and services
- Medipal AI Comprehensive AI agent platform specialized for hospitals and clinics that provides various AI agents for hospital workflow optimization. It integrates all patient communications and AI agent operations into a single solution, enabling real-time hospital management through AI agents that collaborate with medical staff across phone, KakaoTalk, Naver Talk Talk, Instagram, LINE, WhatsApp, and WeChat channels.
- AfterDoc Subscription-based SaaS patient management platform for hospitals and clinics that improves re-examination rates and post-treatment management. It is now integrated into the Medipal AI platform as the core patient management module.
Quantifiable outcome
- Over 500 hospitals and clinics using the platform
- +3 more outcomes
Companies that use Medipal
Customer profileNamed customers7 records
Segments1 record
Ideal customer profiles1 record
Medipal technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration6 records
AI capability6 records
Feature7 records
Medipal partnerships and signals
Strategic signalScale indicators5 records
Recent moves5 records
Expansion highlights5 records
Medipal competitors and assessment
Company assessmentRegional players
- Lunit: Lunit is a Korean AI healthcare company specializing in medical imaging AI (chest X-ray, mammography). Same Korean AI-healthcare ecosystem and hospital customer base, but focused on diagnostics rather than patient communication.
- VUNO: VUNO is a Korean medical AI company developing AI solutions for radiology, pathology, and patient monitoring. Comparable as another Korean AI-healthcare vendor with overlapping hospital customers, though different product focus.
Direct peers
- Suki AI: Suki provides an AI assistant (voice + ambient) for clinicians focused on documentation and workflow tasks. Comparable enterprise B2B AI-for-hospital-workflow positioning, though focused on clinician-side documentation rather than patient communication.
- Notable: Notable builds AI agents that automate hospital administrative and clinical workflows (intake, scheduling, follow-up). Directly comparable to Medipal's AI agent platform model for healthcare workflow automation.
- Kakao Healthcare: Kakao Healthcare is the healthcare arm of Kakao (operator of KakaoTalk), building digital health services on top of the same messaging channel Medipal integrates with. Highly comparable as a Korean patient-engagement platform leveraging KakaoTalk, with significantly stronger platform distribution leverage.
- Augmedix: Augmedix uses AI + remote human assistance to automate medical documentation and clinical workflows for hospitals. Similar hospital enterprise SaaS model with AI-driven workflow automation, comparable customer profile of US health systems.
- Hippocratic AI: Hippocratic AI develops LLM-based agents for healthcare, including patient-facing and workflow automation use cases. Comparable AI-agent architecture targeted at non-clinical hospital tasks similar to Medipal's patient communication agents.
Emerging players
- Olive AI: Olive (formerly Olive AI) pioneered AI-driven hospital workflow automation for revenue cycle and administrative tasks in the US market. Closely comparable hospital-AI-workflow thesis, though primarily revenue-cycle focused.
- Ada Health: Ada Health offers AI-driven symptom assessment and patient triage, with some enterprise integrations into health systems. Comparable AI patient-engagement capability, though focused on symptom assessment rather than multi-channel hospital communication workflows.
Broad incumbents
- Athenahealth: Athenahealth is a large US health IT vendor offering EHR, patient engagement, and revenue cycle solutions to hospitals and clinics. Overlaps with Medipal's patient communication and workflow module at a broader portfolio level.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Medipal social profiles
Digital presenceMedipal financial estimates
Financial estimateRevenue estimate
Valuation estimate
Medipal leadership team
Management profileNumber of profiles
Profiles1 record
Medipal funding detail
Funding detailFunding overview
Funding rounds3 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Medipal M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Medipal
What does Medipal do?
Medipal sells the Medipal AI platform and AfterDoc, a subscription SaaS solution that deploys domain-specialized AI agents in hospitals and clinics to automate patient inquiries (across KakaoTalk, Naver Talk Talk, LINE, WhatsApp, WeChat, Instagram, and phone), re-examination scheduling, post-treatment management, and broader in-hospital workflow optimization. The platform is sold on a recurring subscription basis to healthcare institutions in South Korea, with hospital-specific AI training and one-click agent activation.
Is Medipal a public or private company?
Medipal is a private company. It is classified as venture growth investor backed and is currently operating.
When was Medipal founded?
Medipal was founded in 2020. It employs 11 to 50 people.
Where is Medipal based?
Medipal is headquartered in Mapo, South Korea, in the Asia region.
How does Medipal make money?
One revenue line is on record: saaS Subscription for Healthcare Institutions.
Who are Medipal's main competitors?
Regional players on record are Lunit and VUNO. Direct peers are Suki AI, Notable, Kakao Healthcare, Augmedix and Hippocratic AI. Emerging players are Olive AI and Ada Health. Athenahealth is listed as a broad incumbent.
Does Medipal have an API?
No public API is recorded for Medipal.
What industry is Medipal in?
Medipal's product category is Healthcare Workflow Automation Software. Its primary akta.pro industry code is HLACAEAJ, Adherence, Reminders & Engagement Automation (Medication/Follow-up), with a secondary code of HLACAFAH, Virtual Nursing, Telemonitoring & Command Center Platforms. Its NAICS code is 54151 and its SIC code is 8000.